| Literature DB >> 18252102 |
Vsevolod A Vladimirtsev1, Raisa S Nikitina, Neil Renwick, Anastasia A Ivanova, Al'bina P Danilova, Fyodor A Platonov, Vadim G Krivoshapkin, Catriona A McLean, Colin L Masters, D Carleton Gajdusek, Lev G Goldfarb.
Abstract
Viliuisk encephalomyelitis is an acute, often fatal, meningoencephalitis that tends to develop into a prolonged chronically progressive panencephalitis. Clinical, neuropathologic, and epidemiologic data argue for an infectious cause, although multiple attempts at pathogen isolation have been unsuccessful. To assess mechanisms of disease transmission and spread, we studied 6 multiplex families. Secondary cases occurred among genetically related and unrelated persons in a setting of prolonged intrahousehold contact with a patient manifesting the disease. Transmission to unrelated persons was documented in a densely populated region around the city of Yakutsk in which Viliuisk encephalomyelitis had not been previously known. Initially identified in a small Yakut-Evenk population on the Viliui River of eastern Siberia, the disease subsequently spread through human contacts to new geographic areas, thus characterizing Viliuisk encephalomyelitis as an emerging infectious disease.Entities:
Mesh:
Year: 2007 PMID: 18252102 PMCID: PMC2857279 DOI: 10.3201/eid1309.061585
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
FigureLocation of families with Viliuisk encephalomyelitis characterized in this report. Arrow indicates the general direction of Viliuisk encephalomyelitis dispersion from traditional disease-endemic areas on the Viliui River to densely populated regions of the Sakha (Yakut) Republic around the capital city of Yakutsk.
Clinical features of Viliuisk encephalomyelitis in affected members of 6 families*
| Feature | Family 1 | Family 2 | Family 3 | Family 4 | Family 5 | Family 6 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-1 | 1-2 | 1-3 | 2-1 | 2-2 | 3-1 | 3-2 | 4-1 | 4-2 | 4-3 | 5-1 | 5-2 | 6-1 | 6-2 | 6-3 | |
| Sex | F | F | F | F | F | F | M | M | F | F | F | F | M | F | F |
| Age at onset, y | 16 | 38 | 26 | 16 | 44 | 31 | 21 | 51 | 47 | 36 | 20 | 34 | 46 | 37 | 53 |
| Febrile stage of illness | |||||||||||||||
| Duration, wk | 7 | 11 | 2 | 2 | 10 | ND | 2 | ND | ND | 4 | ND | 1 | ND | 6 | 26 |
| Maximum temperature, oC | 40.5 | 39 | 38 | 37.9 | 39.8 | 39.0 | 39.0 | ND | 38.5 | 38.8 | |||||
| Reduced level of consciousness | ++ | +++ | + | +++ | + | ++ | + | +++ | |||||||
| Generalized seizures | ++ | + | + | ||||||||||||
| Neck rigidity and Kernig sign | + | ++ | + | ++ | + | + | + | ||||||||
| Nausea, vomiting | + | ++ | + | ++ | ++ | + | |||||||||
| Upper motor neuron pattern of muscle weakness | + | + | + | + | |||||||||||
| Relapse of febrile illness | + | + | + | + | |||||||||||
| Outcome | a | d | a | a | d | a | a | a | a | a | a | a | a | a | d |
| Advanced disease | |||||||||||||||
| Cognitive decline | ++ | + | ++ | m.i. | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | |||
| Apathy | + | + | ++ | + | + | + | + | ||||||||
| Dysarthria | +++ | ++ | ++ | ++ | + | ++ | + | ++ | + | + | |||||
| Dysphagia | + | + | + | + | |||||||||||
| Brisk deep tendon reflexes | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | + | ++ | + | ++ | |||
| Spastic tetraparaparesis | +++ | + | ++ | + | ++ | + | ++ | +++ | – | + | + | – | |||
| Increased muscle tone | + | + | + | + | ++ | + | + | ++ | – | + | + | ||||
| Babinski sign | + | + | + | + | + | + | + | + | |||||||
| Spastic gait | +++ | ++ | ++ | + | +++ | + | + | + | + | + | + | + | |||
| Falls | + | ++ | + | + | + | ||||||||||
| Sphincter dysfunction | + | ++ | ++ | + | |||||||||||
| Extrapyramidal rigidity | + | + | ++ | + | ++ | ++ | + | + | + | + | |||||
| Obesity | + | + | + | + | |||||||||||
| Cachexia |
| + |
|
| + |
|
|
|
| ++ |
|
|
|
| + |
| Overall duration of illness | 18 mo | 11 wk | A | 48 mo | 10 wk | 17 y | 24 mo | 9 y | 6 y | 11 mo | 11 y | 23 mo | 13 y | 27 mo | 26 wk |
*ND, not documented; m.i., memory impairment; +, mild; ++, moderate; +++, strong; –, not expressed; d, died within acute phase; a, advanced disease developed; A, alive.
Laboratory investigations and postmortem findings in Viliuisk encephalomyelitis patients from 6 families*
| Laboratory and postmortem findings | Family 1 | Family 2 | Family 3 | Family 4 | Family 5 | Family 6 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-1 | 1-2 | 1-3 | 2-1 | 2-2 | 3-1 | 3-2 | 4-1 | 4-2 | 4-3 | 5-1 | 5-2 | 6-1 | 6-2 | 6-3 | |
| Cerebrospinal fluid | |||||||||||||||
| Cell count (cells/μL) | 20–102 | 8 | 3 | 45–62 | 15–44 | 2 | 11–58 | 25 | 17 | 4– 18 | NA | 12 | NA | 17–65 | 11–27 |
| Predominant cell type | Lym | Lym | Lym | Lym | Lym | Lym | |||||||||
| Protein (mg/dL) | 150 | 166 | 23 | 480 | 99 | 16 | 99 | 33 | 66 | 132 | 66 | 66 | 99 | ||
| Bacterial culture | Neg | Neg | NA | Neg | Neg | NA | Neg | NA | NA | NA | NA | Neg | Neg | ||
| Postmortem | |||||||||||||||
| Inflamed meninges | + | + | + | + | + | + | |||||||||
| Micronecrotic lesions in the brain parenchyma | + | + | + | + | + | + | |||||||||
*NA, data not available; Lym, lymphocytes; Neg, negative; +, observed.